Sustainable Investor
Americas
-
Brazil’s $4 Billion Climate Finance Plan Signals Shift in Emerging Market Capital Strategy
July 29, 2025As the host nation for COP30, Brazil is positioning itself at the centre of the global climate finance agenda. The country’s state development bank, BNDES, confirmed this week that it is in advanced talks with global investors—including Brookfield, TPG, and...
-
US States’ Climate Ambition Under Threat
April 16, 2025Investors urged to “fill the gap” as Trump administration seeks to smother climate rules at the state level.
-
SEC Rule Changes Force Investors to Hold Fire
April 9, 2025UnitedHealth Group is the latest company to utilise new guidance, as shareholders figure out their shifting rights.
-
Investors Keep Tech Bros in Sights
March 17, 2025President Trump’s "bullying" tactics have prompted US-based firms to water down ESG commitments, while investors maintain support for DEI, fair voting rights, responsible tax.
-
US Shareholders Fight Back Against “Coordinated Attack”
February 24, 2025Industry experts highly concerned over SEC rule changes, as investor-led report looks to galvanise pushback on infringed rights.
-
Investors Demand US SEC Delay Shareholder Proposal Changes
February 19, 2025Late introduction of new guidance from the commission risks detrimentally affecting investors during upcoming proxy season.
-
US States Strike Back on Climate Disclosure
February 17, 2025Undaunted by Trump’s 180-degree turn on environmental policies, New York recently followed in California’s footsteps with a corporate data accountability bill.
-
Majority of US Pensions Disappoint on Climate
February 10, 2025Sierra Club has emphasised the importance of proxy voting tools to demonstrate climate-related ambition across states.
-
Trump’s Shadow Looms Over US Corporate Pensions
February 5, 2025A rule setting parameters for employer-sponsored retirement plans to consider ESG factors appears under threat.
-
Investors Urged to Prioritise Accessible US Healthcare
January 31, 2025Donald Trump’s decision to repeal existing measures unlikely to dissuade investors from engaging with pharmaceutical companies.
